# US 2008/0187960 A1 · Non-Cytotoxic Protein Conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187960 A1
- Document ID: US20080187960A1
- Status: Published application
- Kind: A1
- Application number: 11/829,118
- Filed: 2007-07-27
- Published: 2008-08-07
- Earliest claimed: 2004-12-01
- Assignees: Syntaxin Limited; Allergan, Inc.
- Inventors: Keith Foster; John Chaddock; Charles Penn; Kei Roger Aoki; Joseph Francis; Lance Steward
- Web page: https://patentgrep.com/patent/US20080187960A1

## CPC

- C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695)
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/6415: {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- C07K 14/33: from Clostridium (G)
- C12N 9/6489: {Metalloendopeptidases (3.4.24)}
- C12N 15/62: DNA sequences coding for fusion proteins
- C12Y 304/24069: Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
- C07K 2319/00: Fusion polypeptide
- C07K 2319/01: containing a localisation/targetting motif
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

A non-cytotoxic protein conjugate for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell, comprising: (i) a Targeting Moiety (TM), wherein said TM is an agonist of a receptor present on said nociceptive sensory afferent cell, and wherein said receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of said nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described.

## Claims

### Claim 1

A polypeptide comprising first, second and third domains, wherein:
(a) said first domain comprises a botulinum neurotoxin light chain;
(b) said second domain comprises a botulinum neurotoxin heavy chain translocation domain HN; and
(c) said third domain comprises the polypeptide sequence of SEQ ID NO. 14.

### Claim 2 (depends on 1)

A nucleic acid encoding a polypeptide according to claim 1.

### Claim 3 (depends on 2)

The nucleic acid according to claim 2 comprising the nucleic acid sequence of SEQ ID NO. 13.

### Claim 4 (depends on 2)

A nucleic acid vector comprising a nucleic acid according to claim 2.

### Claim 5 (depends on 4)

A method of producing a polypeptide comprising expressing a nucleic acid vector as set forth in claim 4, wherein said polypeptide comprises first, second and third domains, and wherein:
(a) said first domain comprises a botulinum neurotoxin light chain;
(b) said second domain comprises a botulinum neurotoxin heavy chain translocation domain HN; and
(c) said third domain comprises the polypeptide sequence of SEQ ID NO. 14.
